The Limited Times

Now you can see non-English news...

Johnson & Johnson announces that its covid vaccine is 66% effective

2021-01-29T14:55:32.615Z


The drug shows a lower protective capacity against the South African variant A utility prepares a Johnson & Johnson vaccine during trials, in an image provided by the company. The US pharmaceutical Johnson & Johnson announced this Friday that its single-dose coronavirus vaccine has an overall efficacy of 66% in preventing the disease, in a large trial against multiple variants carried out on three continents. In the tests, in which almost 44,000 volunteers participated, t


A utility prepares a Johnson & Johnson vaccine during trials, in an image provided by the company.

The US pharmaceutical Johnson & Johnson announced this Friday that its single-dose coronavirus vaccine has an overall efficacy of 66% in preventing the disease, in a large trial against multiple variants carried out on three continents.

In the tests, in which almost 44,000 volunteers participated, the level of protection against moderate and severe covid-19 ranged from 72% in the United States to 66% in Latin America and only 57% in South Africa, from where has spread a worrying variant.

The first two licensed vaccines, Pfizer and BioNTech and Moderna, set the bar very high, showing about 95% efficacy in preventing symptomatic disease in trials.

However, these tests were conducted primarily in the United States and before new variants such as the South African and the British emerged.

Johnson & Johnson's primary goal was the prevention of moderate to severe covid.

The vaccine was 85% effective in preventing severe disease and hospitalization in all geographic areas and against multiple variants 28 days after immunization.

This "will potentially protect hundreds of millions of people from the serious and deadly results of COVID-19," said Paul Stoffels, the pharmaceutical's scientific director, in a statement with the results, based on 468 symptomatic cases.

Johnson & Johnson plans to apply for emergency use authorization from the US Drug Administration (FDA) next week.

Unlike the Pfizer and BioNTech and Moderna vaccines, Johnson & Johnson's does not require a second injection weeks after the first, nor does it need to be kept frozen, making it a good candidate for use in locations where infrastructure transport and cold storage are insufficient.

Information about the coronavirus

- Here you can follow the last hour on the evolution of the pandemic

- Restrictions search engine: What can I do in my municipality?

- This is how the coronavirus curve evolves in the world

- Download the tracking application for Spain

- Guide to action against the disease

Source: elparis

All life articles on 2021-01-29

You may like

Trends 24h

Life/Entertain 2024-03-28T17:17:20.523Z

Latest

© Communities 2019 - Privacy

The information on this site is from external sources that are not under our control.
The inclusion of any links does not necessarily imply a recommendation or endorse the views expressed within them.